Paul A Mahon sold $2.9M of UTHR
EVP & GENERAL COUNSEL at UNITED THERAPEUTICS Corp. 7,700 shares at an average of $374.37, traded Dec 5, 2024, filed Dec 6, 2024.
Score components
- +15RoleOfficer
- +25Trade size$2.9M at market
- +5Share of holdings soldSold 17% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001562180-24-008216, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 5, 2024 | MOption exercise Common Stock10b5-1 | +7,700 | $163.30 | $1.3M | 44,410 | Dec 6, 2024 |
| Dec 5, 2024 | SOpen-market sale Common Stock10b5-1 | -7,700 | $374.37 | $2.9M | 36,710 | Dec 6, 2024 |
| Dec 5, 2024 | MOption exercise Share Tracking Awardderivative10b5-1 | -7,700 | $0.00 | $0 | 45,050 | Dec 6, 2024 |
Related signals
Other insiders at UNITED THERAPEUTICS Corp and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 23Weak | sell 210b5-1 | UTHR UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $4.5M | 9,500 | |
| 30Weak | sell 310b5-1 | UTHR UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $4.6M | 9,500 | |
| 30Weak | sell 310b5-1 | UTHR UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $4.5M | 9,500 | |
| 30Weak | sell 310b5-1 | UTHR UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $4.5M | 9,500 | |
| 30Weak | sell 310b5-1 | UTHR UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $4.7M | 9,500 | |
| 30Weak | sell 310b5-1 | UTHR UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $4.7M | 9,500 | |
| 30Weak | sell 310b5-1 | UTHR UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $4.7M | 9,500 | |
| 30Weak | sell 310b5-1 | UTHR UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $4.7M | 9,500 | |
| 25Weak | sell 310b5-1 | UTHR UNITED THERAPEUTICS Corp | Paul A Mahon EVP & GENERAL COUNSEL | $4.1M | 8,300 | |
| 30Weak | sell 310b5-1 | UTHR UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $4.7M | 9,500 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.